Aridis focuses on anti-infective alternatives to conventional antibiotics


>> More News

Mining the human immune response for rare monoclonal antibodies to fight infections

Jul 14th, 2015

Aridis Pharmaceuticals Appoints Fred Kurland as Chief Financial Officer (More)

Jul 08th, 2015

Aridis Pharmaceuticals Expands Phase 2a Trial Into the U.S. for Monoclonal Antibody AR-301 for the Treatment of Acute Pneumonia (More)

Jun 30th, 2015

Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin™ for Treating Hospital-Acquired and Ventilator-Associated Pneumonia (More)

Apr 09th, 2015

Aridis Pharmaceuticals Adds Craig Gibbs, Ph.D., MBA, to Board of Directors.  (More)